Ankylosing spondylitis – the current situation and new therapeutic options

Česká verzia

Authors: D. Žlnay; M. Žlnay; J. Rovenský
Authors place of work: Národný ústav reumatických chorôb, Piešťany, Slovenská republika, riaditeľ prof. MUDr. Jozef Rovenský, DrSc., FRCP
Published in the journal: Vnitř Lék 2006; 52(7-8): 730-735
Category: 130th Internal Medicine Day - Rheumatology in clinical practice

Summary

Ankylosing spondylitis (AS) is a chronic, immunologically mediated rheumatic disease whose progression largely depends on the extent of inflammatory activity. In contrast to rheumatoid arthritis (RA), therapeutic control of AS is very limited. Therapy of ankylosing spondylitis should not only control inflammatory processes, but also prevent structural damages and maintain the functions. Until recently, physiotherapy and non-steroidal antiphlogistics (NSA) therapy was a gold standard of AS treatment. NSA therapy alleviates inflammatory pain of spine in 60 to 80% of patients. According to the most recent findings, long-term administration of NSA can affect also X-ray progression. DMARD therapy, which is efficient in RA, has insignicant effect on axial form of AS. Sulfasalazine proved to be efficacious against peripheral form of AS; administration of MTX and leflunomide is not supported by controlled studies. Peripheral arthritis and enthesitis is usually treated by short-term application of corticoids. The fact remains that an important role in AS immunopathogenesis is played by TNF α whose increased levels were found in patients with AS in serum, synovial fluid and SI joints. Anti-TNF therapy with infliximab and etanercept proved to be highly efficacious in patients with AS resistant to conventional therapy. Infliximab and etanercept reduced the disease activity (50% improvement in more than half of patients), improved the function and slowed down the structural damage. MRI studies of anti-TNF therapy proved reduction of inflammatory activity in SI joints and spine. Other studies verified the efficacy of adalimumab in AS therapy and showed that adalimumab is a promising drug. Also, several randomized clinical studies proved efficacy of thalidomide whose administration, however, is limited by its severe adverse effects. Until now, the results of studies focused on pamidronate therapy appear to be rather controversial. Better understanding of AS pathogenesis led to implementation of new therapeutic procedures that significantly improve activity and functional condition of patients.

Key words:
ankylosing spondylitis – biological therapy – anti-TNF-therapy

Zdroje

1. Braun J, Bollow M, Remlinger G et al. Prevalence of spondyloarthropaties in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67.

2. Žlnay D, Matejička F, Rovenský J. Ankylozujúca spondylitída. In: Rovenský J, Pavelka K et al (eds). Klinická reumatológia. Martin: Vydavateľstvo Osveta 2000.

3. Maksymovych WP. Etiology and pathogenesis of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS et al (eds). Rheumatology. 3. ed. New York: Mosby 2003: 1183-1192.

4. Canete JD, Zlena J, Collado A et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropaty. Br J Rheumatology 1997; 36: 38-42.

5. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.

6. Pelletier JP, Caron JP, Evans C et al. In vivo suppression of early experimantal osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012-1019.

7. Kahn MA. Clinical features of ankylosing spondylitis. In: Hochberrg MC, Silman AJ, Smolen JS (eds). Rheumatology. 3. ed. New York: Mosby 2003: 1183-1192.

8. Mau W et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1998; 15: 1109-1114.

9. Van der Linden H et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368.

10. Rudwaleit M et al. The challenge of diagnosis and classification in early AS, do we need new criteria? Arthritis Rheum 2005; 52: 1000-1008.

11. Braun J et al. Imaging and scoring in ankylosing spondylitis. Best Pract Clin Rheumatol 2002; 16: 573-604.

12. Amor B et al. Predictive factors for the longterm outcome of spondyloarthropaties. J Rheumatol 1994; 21: 1789-1790.

13. Amor B et al. Are classification criteria for SpA usefull as diagnostic criteria? Rev Rheum Engl Ed 1995; 62: 10-15.

14. Dougados M, Dijkmans B, Khan MA et al. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61 (Suppl 3): iii40-iii50.

15. Ward MM. Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms? Arthritis Rheum 2005; 52: 1634-1636.

16. Dougados M et al. Efficacy of celecoxib, a COX-2 specific inhibitor, in ankylosing spondylitis: a placebo and conventional NSAID controlled study. Arthritis Rheum 2001; 44: 180-185.

17. Wanders A et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in ankylosing spondylitis: a randomised clinical trial. Arthritis Rheum 2005; 52: 1756-1765.

18. Dougados M et al. Sulphasalazine in the treatment of spondyloarthropaty. A randomised, multicenter, double-blind, placebo controlled study. Arthritis Rheum 1995; 38: 618-627.

19. Haibel G et al. Six months open labal trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64: 124-126.

20. Huang F et al. One-year open label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002; 43: 249-254.

21. Maksymowych W et al. A 6-month randomised, controlled, double-blind, dose response comparison of i.v. pamidronate (60 mg vs. 10 mg) in the treatment of NSA refractory ankylosing spondylitis. Arthritis Rheum 2003; 48: 583-584.

22. Gratacos J et al. Serum cytokines (IL-6, TNF-α, IL-1 β, INF-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br j Rheumatol 1994; 13: 175-180.

23. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropaties. Curr Opin Rheumatol 1996; 8: 275-287.

24. Braun J et al. Use o immunohistologic and in situ hybridisation techniques in the examination of sacioiliac joint biopsy sepciment from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499- 505.

25. Braun J et al. First update of the international ASA consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rehum Dis 2006; 65: 316-320.

26. Rudwaleit M et al. Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-670.

27. Braun J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.

28. Van der Heijde D et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results from a randomised, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-591.

29. Davis JC jr et al. Recombinant human tumor necrosis factor recpetor (etanercept) for treating ankylosing spondylitis: a randomised controlled trial. Arthritis Rheum 2003; 48: 3230-3236.

30. Haibel H et al. Adalimumab reduces symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006; 54: 678-681.

31. Tan AL et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004; 63: 1041-1045.

32. Haibel H et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64: 296-298.